Central Retinal Artery Occlusion: Local Intra-arterial Fibrinolysis versus Conservative Treatment, a Multicenter Randomized Trial

医学 视网膜中央动脉阻塞 随机对照试验 视力 眼科 纤溶 不利影响 外科 内科学
作者
Martin Schumacher,Nicole Eter,Bernhard Jurklies,Christine Gall,Isabel Wanke,Claudia Schmoor,H. Maier-Lenz,L. Solymosi,Hartmut Brueckmann,Aljoscha S. Neubauer,Armin Wolf,Nicolas Feltgen
出处
期刊:Ophthalmology [Elsevier BV]
卷期号:117 (7): 1367-1375.e1 被引量:281
标识
DOI:10.1016/j.ophtha.2010.03.061
摘要

Purpose The reported outcomes of central retinal artery occlusion (CRAO) with or without treatment vary considerably. Although local intra-arterial fibrinolysis (LIF) using recombinant tissue plasminogen activator (rtPA) is a promising treatment, outcomes have not been compared in randomized trials. Design Prospective randomized multicenter clinical trial (the European Assessment Group for Lysis in the Eye Study) to compare treatment outcome after conservative standard treatment (CST) and LIF for acute nonarteritic CRAO. Participants Between 2002 and 2007, 9 centers in Austria and Germany recruited 84 patients (40 received CST, 44 received LIF), and data for 82 patients were analyzed. Methods Patients (age 18–75 years) with CRAO, symptoms for 20 hours or less, and best-corrected visual acuity (BCVA) <0.5 logarithm of the minimum angle of resolution (logMAR) were randomized to the CST or LIF group. Main Outcome Measures The primary end point was BCVA after 1 month; the secondary end point was safety. Results The mean interval between first symptoms and therapy was 10.99±5.49 hours (CST) and 12.78±5.77 hours (LIF). The mean BCVA (logMAR) improved significantly in both groups (CST: −0.44 [standard deviation 0.55]; LIF: −0.45 [standard deviation 0.55]; both P < 0.0001) and did not differ between groups (P=0.69). Clinically significant visual improvement (≥0.3 logMAR) was noted in 60.0% (CST) and 57.1% (LIF) of patients. Two patients in the CST group (4.3%) and 13 patients in the LIF group (37.1%) had adverse reactions. Because of apparently similar efficacy and the higher rate of adverse reactions in the LIF group, the study was stopped after the first interim analysis at the recommendation of the data and safety monitoring committee. Conclusions In light of these 2 therapies' similar outcomes and the higher rate of adverse reactions associated with LIF, we cannot recommend LIF for the management of acute CRAO. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article. The reported outcomes of central retinal artery occlusion (CRAO) with or without treatment vary considerably. Although local intra-arterial fibrinolysis (LIF) using recombinant tissue plasminogen activator (rtPA) is a promising treatment, outcomes have not been compared in randomized trials. Prospective randomized multicenter clinical trial (the European Assessment Group for Lysis in the Eye Study) to compare treatment outcome after conservative standard treatment (CST) and LIF for acute nonarteritic CRAO. Between 2002 and 2007, 9 centers in Austria and Germany recruited 84 patients (40 received CST, 44 received LIF), and data for 82 patients were analyzed. Patients (age 18–75 years) with CRAO, symptoms for 20 hours or less, and best-corrected visual acuity (BCVA) <0.5 logarithm of the minimum angle of resolution (logMAR) were randomized to the CST or LIF group. The primary end point was BCVA after 1 month; the secondary end point was safety. The mean interval between first symptoms and therapy was 10.99±5.49 hours (CST) and 12.78±5.77 hours (LIF). The mean BCVA (logMAR) improved significantly in both groups (CST: −0.44 [standard deviation 0.55]; LIF: −0.45 [standard deviation 0.55]; both P < 0.0001) and did not differ between groups (P=0.69). Clinically significant visual improvement (≥0.3 logMAR) was noted in 60.0% (CST) and 57.1% (LIF) of patients. Two patients in the CST group (4.3%) and 13 patients in the LIF group (37.1%) had adverse reactions. Because of apparently similar efficacy and the higher rate of adverse reactions in the LIF group, the study was stopped after the first interim analysis at the recommendation of the data and safety monitoring committee. In light of these 2 therapies' similar outcomes and the higher rate of adverse reactions associated with LIF, we cannot recommend LIF for the management of acute CRAO.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
星辰大海应助science采纳,获得10
1秒前
高兴的土豆完成签到,获得积分10
1秒前
丘比特应助机智翼采纳,获得10
2秒前
SciGPT应助勤奋的丸子采纳,获得10
3秒前
3秒前
abc发布了新的文献求助10
3秒前
细斟北斗发布了新的文献求助10
3秒前
4秒前
4秒前
5秒前
5秒前
5秒前
ZY发布了新的文献求助10
5秒前
勤奋的真发布了新的文献求助30
6秒前
毛毛虫完成签到,获得积分10
7秒前
hoijuon发布了新的文献求助10
8秒前
Ava应助gsh采纳,获得10
8秒前
swing完成签到,获得积分10
9秒前
yzhdidi发布了新的文献求助10
9秒前
852应助高兴的冰棍采纳,获得10
9秒前
10秒前
小二郎应助七七采纳,获得10
10秒前
王赞应助纳斯达克采纳,获得10
10秒前
11秒前
xy完成签到,获得积分10
11秒前
Chen发布了新的文献求助10
12秒前
13秒前
舍瓦完成签到,获得积分10
13秒前
14秒前
酷酷的安柏完成签到 ,获得积分10
14秒前
14秒前
14秒前
14秒前
感谢有你完成签到 ,获得积分10
15秒前
勤奋的真完成签到,获得积分20
16秒前
16秒前
ZY完成签到,获得积分10
17秒前
17秒前
CINDERICE完成签到,获得积分10
18秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Toward a Combinatorial Approach for the Prediction of IgG Half-Life and Clearance 500
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Picture Books with Same-sex Parented Families: Unintentional Censorship 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3970008
求助须知:如何正确求助?哪些是违规求助? 3514711
关于积分的说明 11175563
捐赠科研通 3250077
什么是DOI,文献DOI怎么找? 1795198
邀请新用户注册赠送积分活动 875630
科研通“疑难数据库(出版商)”最低求助积分说明 804931